VivoSeq
Other

LGMD2I

0

Pipeline Programs↗

1

Active Trials↗

0

Companies Involved↗

LGMD2I is an early-stage landscape with 0 programs across 0 companies.

Intelligence

Pipeline Metrics

Competitive Density

6/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

100/100

Attrition Rate

0/100

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

2

clinical trials

Active, not recruiting1 · 50%
Completed1 · 50%

Clinical Trials

Trial Activity

Study of BBP-418 in Patients With LGMD2I
Active, not recruiting·MML Bio Solutions, Inc.·Phase 2·NCT04800874·14 enrolled
A Trial of PF-06252616 in Ambulatory Participants With LGMD2I
Completed·—·Phase 1/2·NCT02841267·19 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)